PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AbbVie, Roche drug disappoints in phase 3 multiple myeloma trial

Last week, AbbVie reported findings from its phase 3 study, evaluating venetoclax combined with dexamethasone (VenDex) in patients with multiple myeloma who had undergone two or more prior treatments. 

Venetoclax was first approved in 2016 for chronic lymphocytic leukemia under the brand name Venclexta and has since racked up various approvals as a monotherapy or combination treatment, including approval for acute myeloid leukemia (AML) in 2018.

Co-development partners AbbVie and Roche’s Genentech were hoping to expand the drug into a subset of multiple myeloma — patients with the t(11;14) biomarker.

But the latest results, presented at the International Myeloma Society Annual Meeting in Athens, Greece, revealed that the combination treatment did not significantly improve progression-free survival compared to pomalidomide and dexamethasone (PomDex) in t(11;14)-positive relapsed or refractory multiple myeloma patients. 

In the VenDex group, more patients responded well with a 62% overall response rate, and 39% achieved very good partial responses or better, compared to the PomDex group, where these rates were 35% and 14%, respectively. Median overall survival was also longer in the VenDex group, at 32.4 months versus 24.5 months in the PomDex group.

Although the study’s primary endpoint wasn’t met, AbbVie plans to discuss the data’s potential with health authorities regarding venetoclax as a biomarker-driven therapy in multiple myeloma.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026